Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, announced the submission of a Type II Variatio...
InSphero, the global leader in 3D cell culture technology, and scientists from the U.S. Food and Drug Administration's (FDA) National Cente...
AtomVie Global Radiopharma (AtomVie), a leading radiopharmaceutical Contract Development and Manufacturing Organization (CDMO), has entered into an agreeme...
Amgen (NASDAQ:AMGN) announced the presentation of positive top-line results from the Phase 3 MINT trial evaluating the efficacy and safety of UPLIZNA&...
First Phase 3 PDT study in patients with sBCC in the United States. Rigorous dual endpoints requiring complete clinical and cytological clearance of m...
Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with GMP facilities in Belgium, Spain, the Netherlan...
First FDA-approved abbreviated new drug application (ANDA) to reference medicine Single-dose 100 mg vial for intravenous use, approved for metastatic ...
Dizal (, a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that th...
Aileron Therapeutics, a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs i...
Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine prophylaxis ...
Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), an innovative company in the field of precision onco...
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and ten23 health, the human-centri...
Indiana facility will combine research, manufacturing and the latest technology to innovate new production methods and scale glo...
Hovione Farmaciência, S.A.(“HOVIONE”) and Zerion Pharma A/S (“ZERION”) today announced that they have expanded their part...
© 2025 Biopharma Boardroom. All Rights Reserved.
